Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure

Otros usuarios también vieron estos artículos

Ultrasound tenosynovitis: A differential feature of patients with seronegative rheumatoid arthritis Santiago Ruta, Einer Sanchez Prado, Facundo Salvatori, Juan Arguello, Darío Aguerre, Sebastián Magri, Rodrigo García Salinas

10.1016/j.reuma.2022.04.003

Minimum Effective Dosages of Anti-TNF in Rheumatoid Arthritis: A Cross-sectional Study Inmaculada de la Torre, Lara Valor, Juan Carlos Nieto, María Montoro, Luis Carreño

10.1016/j.reuma.2013.07.009

Extension of the RENACER Study: 12-Month Efficacy, Safety and Certolizumab PEGol Survival in 501 Rheumatoid Arthritis Patients Vicenç Torrente-Segarra, Manuel Fernández Prada, Rosa Expósito, Noemí Patricia Garrido Puñal, Amalia Sánchez-Andrade, José Ramón Lamúa-Riazuelo, Alejandro Olivé, Juan Víctor Tovar

10.1016/j.reuma.2018.12.004